Skip to main content
Fig. 8 | Alzheimer's Research & Therapy

Fig. 8

From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Fig. 8

Observed mean change from baseline in A amyloid PET SUVr, B amyloid Centiloid, C plasma Aβ42/40 ratio (standardized value), and D Plasma p-tau181 (standardized value) during study 201 core, gap period, and OLE phase (OLE enrolled set). F/up = 90-day follow-up period following study 201 core

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193